Form D · Biotechnology
Nectero Medical Inc
Tempe, AZ · CIK 0001810951
Offering snapshot reported May 10, 2024 · SEC filing
- Reported sold
- $32.8M Offering amount: $96.6M
- Investors reported
- 30 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 4, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 10, 2024 | Initial | $32,791,551 | No comparison | 30 | SEC filing |
| Sep 1, 2021 | Initial | $18,189,496 | No comparison | 31 | SEC filing |
| Apr 30, 2020 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-512920
Series D Preferred Stock
Source: Form D, filed May 10, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Anil Dasu | Director |
| Colin Morrison | Director |
| Bruce Roberts | Director |
| Jack Springer | Director, Executive |
| John Springer | Director, Executive |
| Robert Whirley | Director |
| Bryan Ziegler | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2343 W. University Drive Suite D103
Tempe, AZ, 85281
Tempe, AZ, 85281